Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd Ordinary Shares GTSIF

Healthcare Drug Manufacturers - Specialty & Generic
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.


OTCPK:GTSIF - Post by User

Lobe Sciences Ltd Ordinary Shares > NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by fTrudeauon Jun 15, 2022 4:45pm
119 Views
Post# 34759440

RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼

RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
i read the news release. Doesn't mention much about 2023 but this company definitely has major potential... I wonder how FDA meeting will be in 3rd Q of 2022. They did a share split recently which is beneficial as to not worry about this occuring again. I dig how to the CEO stated he wants to keep shareholders updated.... Many out there do not outright say this. Added to watch list.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities